All In Biotech

Drug Trial Radar · NCT07007559

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

Protocol ASPEN-09-03: A Single-arm Phase 2 Multicenter Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Participants With Metastatic HER2-Positive Breast Cancer, a Substudy Under Master Protocol ASPEN-09: A Phase 1b/2, Multicenter, Multi Arm Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Dec 10, 2025

Primary completion

Dec 2027

Study completion Dec 2028

Sponsor

Lead sponsor
ALX Oncology Inc.Industry
Sponsor type
Industry
First posted
Jun 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Substudy Protocol ASPEN-09-03 is a Phase 2, single-arm, multicenter study evaluating the efficacy, safety, and tolerability of evorpacept in combination with trastuzumab and chemotherapy in participants with HER2-positive metastatic breast cancer who have previously received trastuzumab-deruxtecan. This substudy is actively recruiting. ASPEN-09-03 is a substudy under Master Protocol ASPEN-09, and additional substudies are as follows: * Metastatic colorectal cancer (CRC) - dose escalation phase to evaluate evorpacept in combination with other drugs. This substudy is not open. * Recurrent/metastatic head and neck cancer (HNSCC) - dose escalation phase to evaluate evorpacept in combination with other drugs. This substudy is not open.

Conditions

  • Breast Cancer, Metastatic

Interventions

  • Evorpacept (ALX148)Drug

    IV infusion

  • TrastuzumabDrug

    IV infusion

  • PaclitaxelDrug

    IV infusion

  • CapecitabineDrug

    Oral administration

  • EribulinDrug

    IV infusion

  • GemcitabineDrug

    IV infusion

  • VinorelbineDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR) using RECIST v1.1 based on BICR assessmentTime frame: Approximately 6 months after the last participant is enrolled

Locations

61 sites in 8 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Building-Phoenix

    Phoenix, Arizona · Recruiting

  • The University of Arizona Cancer Center - North Campus

    Tucson, Arizona · Recruiting

  • City of Hope

    Duarte, California · Recruiting

  • UC San Diego Moores Cancer Center

    La Jolla, California · Recruiting

  • UC Irvine Health - Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • Saint Joseph Hospital - Cancer Centers of Colorado

    Denver, Colorado · Withdrawn

  • Lutheran Hospital - Cancer Centers of Colorado

    Golden, Colorado · Recruiting

  • Saint Mary's Regional Hospital - Cancer Centers of Colorado

    Grand Junction, Colorado · Recruiting

  • The George Washington Medical facility Associates

    Washington D.C., District of Columbia · Recruiting

  • Mayo Clinic

    Jacksonville, Florida · Recruiting

  • Sylvester Comprehensive Cancer Center

    Miami, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • City of Hope Chicago

    Zion, Illinois · Recruiting

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan · Recruiting

  • Mayo Clinic Cancer Center

    Rochester, Minnesota · Recruiting

  • HealthPartners Frauenshuh Cancer Center

    Saint Louis Park, Minnesota · Recruiting

  • Washington University School of Medicine- Siteman Cancer Center

    St Louis, Missouri · Recruiting

  • St. Vincent Regional Hospital - Cancer Centers of Montana

    Billings, Montana · Recruiting

  • Oncology Hematology West, Pc Dba Nebraska Cancer Specialists

    Omaha, Nebraska · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Duke Cancer Institute

    Durham, North Carolina · Recruiting

  • Gabrail Cancer Center

    Canton, Ohio · Recruiting

  • Oregon Health and Science University

    Portland, Oregon · Recruiting

  • University of Texas Southwestern Medical Center

    Dallas, Texas · Recruiting

  • Houston Methodist Cancer Center

    Houston, Texas · Recruiting

  • The University of Texas M.D. Anderson Cancer Center

    Houston, Texas · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

  • University Health Network, Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

  • CHU de Besancon

    Besançon, France · Recruiting

  • Institut Bergonie

    Bordeaux, France · Recruiting

  • Hopital de l'Institut Curie

    Paris, France · Recruiting

  • Hopital Europeen Georges Pompidou (HEGP)

    Paris, France · Recruiting

  • Centre Hospitalier Universitaire (CHU) de Poitiers

    Poitiers, France · Recruiting

  • Centre Eugene Marquis

    Rennes, France · Recruiting

  • Gustave Roussy

    Villejuif, France · Recruiting

  • ASST Papa Giovanni XXIII

    Bergamo, Italy · Recruiting

  • IRCCS Azienda Ospedaliero- Universitaria di Bologna, Policlinico di Sant'Orsola

    Bologna, Italy · Recruiting

  • IRCCS- Istituto Europeo di Oncologia

    Milan, Italy · Recruiting

  • Fondazione IRCCS San Gerardo Dei Tintori

    Monza, Italy · Recruiting

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.